NASDAQ$CCRN

Cross Country Healthcare Inc · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Briefing

Cross Country Healthcare's financial performance declined in Q3 2023 due to challenging market conditions, especially in nursing, but experienced growth in physician staffing, education and homecare staffing.

Cross Country Healthcare reported a revenue of $442.3 million for Q3 2023, a 30% decrease year-over-year and an 18% decrease sequentially. Net income was $12.8 million, with diluted EPS at $0.36, and adjusted EPS at $0.39. The company highlighted growth in physician staffing, education, and homecare staffing, and the signing of a significant Intellify® agreement.

  • Revenue decreased by 30% year-over-year and 18% sequentially.
  • Physician Staffing, Education and Homecare experienced year-over-year revenue growth.
  • Net income attributable to common stockholders was $12.8 million.
  • Company repurchased approximately 600,000 shares of common stock for $14.8 million.

Headline financials

Total Revenue

$442M

Previous: $636M-30.5%
EPS (adj)

$0.39

Previous: $1.07-63.6%
Capital Expenditures

-$11.1M

Previous: -$6.76M-64.1%
Free Cash Flow

$1.71M

Previous: $28M-93.9%
Net Income

$12.8M

Previous: $34.8M-63.2%
Operating Income

$20.3M

Previous: $52.2M-61.1%
Gross Profit

-$345M

Previous: -$493M+30.0%
Cash & Equivalents

$14.3M

Previous: $30.3M-52.8%
Total Assets

$708M

Previous: $883M-19.8%
Stock-Based Comp

$1.43M

Previous: $1.49M-3.9%

Revenue & EPS history

Cross Country Healthcare · Revenue · Quarterly

$442M

Q3 2023-30.5%vs Q3 2022
Beat estimate in 11 of 15 quarters(73%)
ActualEstimate

Revenue by segment

Cross Country Healthcare · $442M total across 2 segments · Q3 2023

  • Nurse and Allied Staffing
    $397M-35.2%
  • Physician Staffing
    $45.7M+91.8%

Forward guidance

For the fourth quarter of 2023, Cross Country Healthcare anticipates revenue between $400 million and $410 million, adjusted EBITDA between $19.0 million and $24.0 million, and adjusted EPS between $0.25 and $0.35.

Headwinds

  • Revenue is projected to decline between 36% and 35% year-over-year.
  • Revenue is projected to decline between 10% and 7% sequentially.
  • Adjusted EBITDA is projected to decline between 67% and 58% year-over-year.
  • Adjusted EBITDA is projected to decline between 30% and 12% sequentially.
  • Adjusted EPS is projected to decline between $0.84 and $0.74 year-over-year.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

-2.7%

Avg return

Earnings day

-1.5%

Avg return

5 days after

+0.5%

Avg return

30 days after

44%

28 / 64 earnings

Positive

+24.6%

Q3 2021

Best reaction

-33.6%

Q2 2010

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.8%+0.4%+0.8%
Q4 2025+8.2%+7.9%+0.5%
Q3 2025-14.1%-7.2%-32.9%
Q1 2025+0.4%+0.8%-6.7%
Q4 2024+0.3%-6.0%-13.9%
Q3 2024+7.2%-6.1%+57.9%
Q2 2024-2.7%-8.2%-17.3%
Q1 2024-4.9%-9.0%-14.1%
Q4 2023-2.7%-0.3%+5.7%
Q3 2023-14.0%-19.0%-10.7%
Q2 2023-14.7%-14.0%-3.8%
Q1 2023+5.1%+9.9%+26.1%
Q4 2022-5.6%+3.2%-13.2%
Q3 2022-2.5%-11.3%-2.8%
Q2 2022-13.7%-14.1%-7.6%
Q1 2022-2.6%-7.1%+0.9%
Q4 2021-1.5%+6.6%+2.4%
Q3 2021+24.6%+18.0%+21.1%
Q2 2021+23.0%+14.6%+29.7%
Q1 2021+16.5%+24.0%+17.4%
Q4 2020+18.9%+24.6%+33.8%
Q3 2020-5.0%-3.0%+9.3%
Q2 2020+9.6%+4.7%+1.6%
Q1 2020-4.8%-2.0%+7.6%
Q4 2019+0.4%-12.2%-27.7%
Q3 2019+14.2%+16.9%+10.9%
Q2 2019-0.8%-5.5%+5.6%
Q1 2019+4.7%+18.7%+0.9%
Q4 2018-3.6%-11.6%-22.5%
Q3 2018+7.8%+3.4%+2.7%
Q2 2018-30.9%-26.0%-14.7%
Q1 2018-16.7%-11.0%-4.3%
Q4 2017-18.8%-13.6%-15.8%
Q3 2017-9.6%-13.8%-2.6%
Q2 2017+3.1%+1.2%+2.5%
Q1 2017-13.0%-15.1%-16.7%
Q4 2016+3.4%-5.3%-7.2%
Q3 2016+22.9%+24.3%+31.7%
Q2 2016-11.5%-17.0%-14.2%
Q1 2016+10.0%
Q4 2015-21.9%
Q3 2015+9.5%
Q2 2015+10.1%
Q1 2015-4.6%
Q4 2014-9.6%
Q3 2014-0.5%
Q2 2014+1.8%
Q1 2014-14.3%
Q4 2013-22.3%
Q3 2013+3.1%
Q2 2013-3.3%
Q1 2013+0.4%
Q4 2009-5.5%
Q3 2012-0.9%
Q2 2012-5.5%
Q1 2011-3.1%
Q1 2012+11.8%
Q4 2011+0.8%
Q3 2010+2.5%
Q3 2011+2.5%
Q2 2011-33.6%
Q4 2010-33.6%
Q2 2010-33.6%
Q1 2010-7.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro